Furthermore, while the Cdkl5 +/− mouse model offers a valuable platform for assessing overexpression toxicity in a context that more closely mirrors the condition in female CDD patients, it is important to note that a thorough safety evaluation should also involve wild-type mice treated with gene therapy. This evidence concerns the gene CDKL5 and craniodiaphyseal dysplasia.